Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Olema Pharmaceuticals Inc (NASDAQ: OLMA) closed the day trading at $25.07 down -2.22% from the previous closing price of $25.64. In other words, the price has decreased by -$2.22 from its previous closing price. On the day, 0.7 million shares were traded. OLMA stock price reached its highest trading level at $25.99 during the session, while it also had its lowest trading level at $24.97.
Ratios:
For a better understanding of OLMA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.03 and its Current Ratio is at 8.03. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Guggenheim on October 08, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On August 12, 2025, Citigroup reiterated its Buy rating and also lowered its target price recommendation from $20 to $21.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $24.Goldman initiated its Buy rating on April 02, 2024, with a $24 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 22 ’25 when Harmon Cyrus sold 2,881 shares for $28.53 per share. The transaction valued at 82,195 led to the insider holds 741,259 shares of the business.
CLARK IAN T sold 264,800 shares of OLMA for $7,873,109 on Dec 19 ’25. The Director now owns 0 shares after completing the transaction at $29.73 per share. On Dec 19 ’25, another insider, Myles David C., who serves as the CH. DISCOV. & NON-CLIN DEV OFF of the company, sold 51,000 shares for $30.46 each. As a result, the insider received 1,553,544 and left with 551,881 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OLMA now has a Market Capitalization of 2009609216 and an Enterprise Value of 1396822272.
Stock Price History:
The Beta on a monthly basis for OLMA is 1.92, which has changed by 3.6032314 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, OLMA has reached a high of $36.26, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is 28.40%, while the 200-Day Moving Average is calculated to be 175.45%.
Shares Statistics:
Over the past 3-months, OLMA traded about 3.80M shares per day on average, while over the past 10 days, OLMA traded about 2406780 shares per day. A total of 68.65M shares are outstanding, with a floating share count of 65.83M. Insiders hold about 16.31% of the company’s shares, while institutions hold 75.28% stake in the company. Shares short for OLMA as of 1765756800 were 11090858 with a Short Ratio of 2.92, compared to 1763078400 on 9364250. Therefore, it implies a Short% of Shares Outstanding of 11090858 and a Short% of Float of 15.010001.
Earnings Estimates
Olema Pharmaceuticals Inc (OLMA) is presently subject to a detailed evaluation by 7.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.51 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$1.83 and -$2.22 for the fiscal current year, implying an average EPS of -$1.93. EPS for the following year is -$2.33, with 6.0 analysts recommending between -$1.86 and -$2.66.
